aTyr Pharma Announces Publication in the Journal mAbs
November 11 2020 - 7:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel biological pathways, today announced a publication
highlighting new technological advances to isolate, characterize
and engineer a diverse, novel family of human antibodies with high
affinity for their target. The paper, titled “Isolation of
monoclonal antibodies from anti-synthetase syndrome patients and
affinity maturation by recombination of independent somatic
variants,” was published in the peer-reviewed journal mAbs. The
research was conducted in collaboration with, AbCellera Biologics,
Inc., a leader in antibody technology and discovery platforms, who
served as a co-author of the publication.
aTyr is leveraging its tRNA synthetase biology
platform to determine novel pathways mediated through extracellular
response. The company is focused on creating new biologics to
modulate these signaling pathways, by either developing a protein
therapy based on a tRNA synthetase or generating monoclonal
antibodies to target the pathway. Engineering techniques that
enhance the affinity and selectivity of antibodies can accelerate
the development of antibody therapeutics against novel targets.
“These findings demonstrate aTyr’s ability to
apply novel approaches that facilitate rapid engineering of
desirable properties into discovered antibodies. Especially
noteworthy is the utilization of natural human antibodies as guides
to provide strategies to generate potential therapeutic
antibodies,” said Sanjay S. Shukla, M.D., M.S., President and Chief
Executive Officer of aTyr. “Some of these findings have already
been applied successfully to generate antibody candidates targeting
Neuropilin-2 (NRP2) in our pipeline. We look forward to building
upon our knowledge related to these enhanced processes as we
continue to advance our antibody program.”
The article may be accessed in the Publications
section of the company’s website at http://www.atyrpharma.com.
About aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
biological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are usually
identified by the use of words such as “anticipates,” “believes,”
“estimates,” “expects,” “intends,” “may,” “plans,” “projects,”
“seeks,” “should,” “will,” and variations of such words or similar
expressions. We intend these forward-looking statements to be
covered by such safe harbor provisions for forward-looking
statements and are making this statement for purposes of complying
with those safe harbor provisions. These forward-looking statements
include statements regarding potential tRNA synthetase or antibody
therapeutic candidates; the potential therapeutic benefits and
applications of our current and future potential product
candidates; timelines and plans with respect to certain development
activities and certain development goals. These forward-looking
statements also reflect our current views about our plans,
intentions, expectations, strategies and prospects, which are based
on the information currently available to us and on assumptions we
have made. Although we believe that our plans, intentions,
expectations, strategies and prospects, as reflected in or
suggested by these forward-looking statements, are reasonable, we
can give no assurance that the plans, intentions, expectations or
strategies will be attained or achieved. All forward-looking
statements are based on estimates and assumptions by our management
that, although we believe to be reasonable, are inherently
uncertain. Furthermore, actual results may differ materially from
those described in these forward-looking statements and will be
affected by a variety of risks and factors that are beyond our
control including, without limitation, uncertainty regarding the
COVID-19 pandemic, risks associated with the discovery, development
and regulation of our product candidates, the risk that we or our
partners may cease or delay preclinical or clinical development
activities for any of our existing or future product candidates for
a variety of reasons (including difficulties or delays in patient
enrollment in planned clinical trials), the possibility that
existing collaborations could be terminated early, and the risk
that we may not be able to raise the additional funding required
for our business and product development plans, as well as those
risks set forth in our most recent Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and in our other SEC filings. Except
as required by law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact: |
Ashlee Dunston |
Director, Investor Relations and
Corporate Communications |
adunston@atyrpharma.com |
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Sep 2023 to Sep 2024